Stress Degradation Studies and HPLC Method Development for Simultaneous Estimation of Prednisolone Acetate and Chloramphenicol in Topical Eye Drops

M. AHSAN HAFIZ^{1,*}, MUHAMMAD IDREES², IMRAN TARIQ¹, SOHAIL AMJAD¹ and ARSHAD ALI SHAH³

¹University College of Pharmacy, University of the Punjab, Lahore-54000, Pakistan

²Department of Chemistry, Government College University, Lahore, Pakistan

³Department of Pharmacy, University of South Asia, Lahore, Pakistan

*Corresponding author: Tel: +92 333 4060054; E-mail: ahsanshareef105@hotmail.com

Received: 5 May 2014;

Accepted: 8 August 2014;

Published online: 6 November 2014;

AJC-16242

A rapid reversed phase liquid chromatographic method was developed and validated for simultaneous HPLC determination of chloramphenicol and prednisolone acetate. The proposed method was effectively applied on separation of chloramphenicol and prednisolone acetate in the presence of excipients and degradation products in eye drops. Chromatographic separation was achieved using combination of ammonium acetate buffer (0.02 M; pH 4) and methanol (30:70 v/v) at a flow rate of 1.5 mL/min. The effluent from column was monitored at 276 and 245 nm for chloramphenicol and prednisolone acetate, respectively. A good linear relationship was observed over the concentration ranges 0.0256-80 and 0.064-200 µg/mL with correlation coefficient 0.9999 and 0.9999 for chloramphenicol and prednisolone acetate, respectively. Calculated LOQ were 36 ng/mL for chloramphenicol and 31 ng/mL for prednisolone acetate. Active ingredients (chloramphenicol and prednisolone acetate) and degradation products were resolved in less than 4 min. The developed method was validated according to ICH guidelines.

Keywords: Reversed phase, Degradation products, Chloramphenicol, Prednisolone acetate.

INTRODUCTION

Corticosteroids have been widely used as anti-inflammatory agents in medicine. Now a days, antibacterials are frequently combined with corticosteroids in pharmaceuticals since corticosteroids are meant to treat inflammation, they may cause temporary masking of the underlying disease *e.g.*, infection. Therefore, combination of steroid with antibiotic is useful to resolve both inflammation and infection¹.

Prednisolone acetate, 11β 17, 21-trihydroxypregna-1,4-diene-3,20-dione 21-acetate (Fig. 1), is a corticosteroid used to treat steroid-responsive inflammatory ocular conditions where ocular bacterial infection or a risk of infection exists². It is differentiated from dexamethasone due to its higher corneal permeability, although its glucocorticoid potency and receptor binding capacity are smaller³. It has been quantitated in multi-component mixtures of natural and synthetic corticosteroids⁴ or as adulterant⁵ in local drugs by HPLC. Chloramphenicol (Fig. 2) is a broad spectrum antibiotic possessing antibacterial activity against Gram positive and Gram negative bacterial infections, used for the treatment of rickettsial and chlamydial diseases and topically for superficial conjunctival infections. The drug acts by binding to 50S subunit in the prokaryotic

Fig. 1. Chemical structure of prednisolone

Fig. 2. Chemical structure of chloramphenicol

cell and thus inhibiting protein synthesis⁶⁻⁸. Prednisolone in conjunction with chloramphenicol is used to cure acute and subacute conjunctivitis. The combination is effective against the following aerobic gram positive and negative bacteria such as *S. aureus*, *S. epidermidis*, *S. pneumonia* and haemophilus influenza⁹.

Literature survey revealed different HPLC methods for concurrent determinations of prednisolone acetate and chloramphenicol in topical formulations. Hongxin¹⁰ described HPLC method for concurrent determination of prednisolone acetate and chloramphenicol in eye drops. Katakam and Sireesha¹¹ developed another HPLC method for simultaneous determination of prednisolone acetate and chloramphenicol in formulations. When these methods were applied to characterize compounds in eye drops of different companies while maintaining the same chromatographic conditions, the methods did not reproduce results as desired. This might be due to the fact that the already developed methods did not confirm robustness of the processes. Method developed by Katakam and Sireesha applied stress testing to individual components separately rather than combined eye drops samples. So there was a need to develop an alternative fast and accurate method involving simultaneous analysis of prednisolone acetate and chloramphenicol in eye drops through HPLC.

The present study with a unique mobile phase composition reports a simple HPLC method for the simultaneous determination of prednisolone acetate and chloramphenicol in the presence of degraded products formed under applied stress conditions. Stress of different types was applied directly to sample solutions. Attempts were made to minimize the analysis time and cost of analysis by optimization of chromatographic conditions. The degraded products demonstrated no interferences with the active drug ingredients measurement. Stress testing provides evidence about the quality of a drug substance under the influence of various factors (acid, base, heat and humidity *etc.*) and aids in establishing shelf life for the drug⁷.

EXPERIMENTAL

Prednisolone acetate was provided as gift sample from Schazoo pharmaceuticals Ltd., Lahore and chloramphenicol was procured from Allergan Pharma, Lahore. HPLC grade methanol was purchased from Sigma Aldrich, USA. Double distilled water was used during the study. The pharmaceutical eye drops containing 1 % prednisolone acetate and 0.4 % chloramphenicol were Prednisynth (Schazoo Laboratories, Lahore), Prednicol (Remington Pharmaceuticals, Lahore) and Predni-C (Mediceena Pharmaceuticals, Lahore) were purchased from market. Ammonium acetate, phosphoric acid, sodium hydroxide and potassium permanganate were sourced from Merck chemicals, USA and were of analytical grade.

Instrumentation and chromatographic conditions: Chromatography was performed with Shimadzu LC 20 AT HPLC system comprising pump, column compartment, UV detector (SPD-M20A) and ultrasonic bath. The system was integrated with LC solutions software. Compounds were separated on Thermo Hypersil C-18 column (250 × 4.6, 5 µm, Runcorn, UK) and elution of components was made by reversed phase mode. The mobile phase was a 70:30 (v/v) mixture of methanol and 0.02 M ammonium acetate buffer (pH 4) and passed through column at a flow rate of 1.5 mL/min. Before passing through the HPLC system, mobile phase was filtered through 0.45 µ nylon filter and degassed in a sonicator (PS, 02000A). The injection volume was 20 µL using rheodyne injector and detection was made by ultraviolet (UV) absorption

at 276 and 245 nm for chloramphenicol and prednisolone acetate, respectively. Chromatographic separation was performed at room temperature (25-30 °C).

Preparation of stock solution: The stock solution of chloramphenicol and prednisolone acetate (0.4 mg/mL and 1 mg/mL, respectively) was prepared by dissolving 10 mg of chloramphenicol and 25 mg prednisolone acetate to a small amount of mobile phase in a 25 mL volumetric flask and then raising the volume up to the mark with mobile phase.

Preparation of working standard solution: 5 mL of standard stock solution was taken accurately in 25 mL volumetric flask. 10 mL of mobile phase was added, mixed and made up to volume. The concentration of working standard solution is 80 and 200 µg/mL for chloramphenicol and prednisolone acetate, respectively.

Preparation of sample (eye drops) solution: Sample solution was prepared by mixing three eye drops of each company. Accurately 1 mL of ophthalmic solution was taken and diluted to 25 mL using mobile phase. The solution was sonicated for 10 min. The concentrations of final sample solutions for chloramphenicol and prednisolone acetate were 80 and 200 µg/mL, respectively.

Linearity: Linearity of the developed method was done by analyzing six solutions in the range of 0.0256 - 80 µg/mL (0.0256, 0.128, 0.64, 3.2, 16 and 80 µg/mL) for chloramphenicol and 0.064 - 200 µg/mL (0.064, 0.32, 1.6, 8, 40 and 200 µg/mL) for prednisolone acetate.

Specificity (forced degradation studies): Assay of the active drug and the degradation products generated during stability studies are the two major determinants of shelf life of a drug product. Therefore, degradation studies were conducted to evaluate the stability of the products as well as to assess the specificity of the method. Four types of degradation studies *i.e.*, acidic, basic, oxidative and thermal were performed.

Acid degradation studies: For this purpose, 5 mL of standard stock solution was added to 25 mL volumetric flask. Then, 0.1 mL of 2N HCl was added and kept at room temperature for 20 min. After completion of the stress, the solution was neutralized with 1.25 N NaOH and was finally diluted up to 25 mL with mobile phase.

Basic degradation studies: These studies were carried out at normal conditions of humidity and temperature using 1.25 N NaOH. For this purpose, 5 mL of standard stock solution was added to 25 mL volumetric flask. 0.06 mL of 1.25 N NaOH was added and kept for 20 min. Then, the solution was neutralized with 2 N HCl solution and was finally diluted up to 25 mL with mobile phase.

Oxidative degradation studies: For performing oxidative stress studies, 5 mL of standard stock solution was added to 25 mL volumetric flask. 0.5 mL of 0.006 KMnO₄ was added and kept for 30 min. Finally, it was diluted to 25 mL with mobile phase.

Thermal degradation studies: For these studies, 5 mL standard stock solution was added to 25 mL round bottom flask equipped with reflux condenser. The solution was undergone reflux for 2 h at 120 °C. Then, it was cooled at room temperature and volume was made up to 25 mL with mobile phase.

Precision: The intra-day precision was demonstrated in terms of % RSD of three different concentrations as used for recovery study by injecting 6 replicate injections of each concentration in same day. The inter day variability was examined for the same solution by injecting 18 replicates in 3 days.

Limits of detection and quantitation: The limit of detection (LOD) and limit of quantitation (LOQ) of the method were calculated on the basis of standard deviation of the response and slope¹² by applying following formula.

$$\text{Limit of detection} = 3.3 \sigma/S$$

$$\text{Limit of quantitation} = 10 \sigma/S$$

where σ is standard deviation of response and s is the slope of the calibration curve. Six replicate injections of mobile phase were injected to calculate standard deviation of response.

RESULTS AND DISCUSSION

Optimization of chromatographic conditions: A number of preliminary experiments were performed to resolve chloramphenicol, prednisolone acetate, excipients and degradation products. Method development was started using 0.02 M ammonium acetate buffer pH 4 and acetonitrile in the ratio of 40:60, 30:70, 35:65 (v/v) for simultaneous determination of chloramphenicol and prednisolone acetate using hypersil C-18 column. By applying these compositions of mobile phase, both chloramphenicol and prednisolone acetate were not resolved in terms of tailing. Then acetonitrile was replaced with methanol and monolithic column was used for better elution but remained unsuccessful. Same composition of mobile phase was tried on Thermo Hypersil C-18 (250 × 4.6 mm, 5 μ m, Runcorr., U.K) column, very sharp peaks of chloramphenicol and prednisolone acetate were obtained. Subsequently, composition of methanol was adjusted to obtain better resolution of chloramphenicol, prednisolone acetate, excipients and degradation products. Upon application of the proposed method, well separated sharp peaks were obtained for both chloramphenicol and prednisolone acetate at retention times of 2.269 and 3.659, respectively. The representative chromatogram of chloramphenicol and prednisolone acetate were given in Fig. 3. The developed chromatographic method was validated in accordance with ICH guidelines¹³.

Fig. 3. Typical chromatogram showing peaks of chloramphenicol and prednisolone acetate

Method validation: Validation parameters performed include specificity, linearity, limit of detection and quantitation, accuracy and precision.

Specificity: Forced degradation studies were performed to establish the specificity. To perform this test 5 mL of the stock solution was treated with 100 μ L HCL (2M) for 20 min, 60 μ L NaOH (1.25 M) for 20 min, 500 μ L KMnO₄ (0.006 M) for 30 min, heat at 120 °C and reflux for 2 h. All the solutions were diluted with mobile phase to a theoretical concentration of 60 and 200 μ g/mL for chloramphenicol and prednisolone acetate respectively. Acidic and alkaline samples were neutralized prior to final dilution. The representative chromatograms of acidic, basic, oxidative and thermal stress tests for chloramphenicol and prednisolone acetate were given in Figs. 4-8, respectively.

Linearity of the method: Linearity of the developed method was done by analyzing six solutions in the range of

Fig 4: Acid stress treated sample analytes

Fig. 5. Chromatogram showing basic stress

Fig. 6. Oxidative stress based degradation

Fig. 7. Chromatogram showing heat induced degradation

Fig. 8. Chromatogram of sample eye drops (Prednisynth) in the presence of excipients

0.00256–80 µg/mL (0.0256, 0.128, 0.64, 3.2, 16 and 80 µg/mL) for chloramphenicol and 0.064–200 µg/mL (0.064, 0.32, 1.6, 8, 40 and 200 µg/mL) for prednisolone acetate. Each concentration was analyzed in triplicate. The peak areas obtained against each concentration of the analytes were used to build a linear regression equation and to determine value of correlation coefficient. Good linearity was observed for chloramphenicol over the range of 0.0256–80 µg/mL with regression line equation = $31273x + 267.6$ and correlation coefficient was found to be 0.9999. For prednisolone acetate, the linearity was found over the range of 0.064–200 µg/mL with linear regression equation and correlation coefficient were calculated to be $35009x + 1843.9$ and 0.9999, respectively. Linearity graph for chloramphenicol and prednisolone acetate are given in Figs. 9 and 10, respectively.

Limit of detection and quantitation: Quantitation is the lowest amount of the analyte which can be quantitatively determined with suitable precision and accuracy but for detection only quantitation as an exact value is required. Limit of quantitation and limit of detection were calculated on the basis of standard deviation of the response and slope¹². By applying formula, LOQ and LOD for chloramphenicol were calculated in the range of 36 and 11 ng/mL, respectively. For prednisolone acetate, LOQ & LOD were 31 and 10 ng/mL, respectively.

Accuracy: Accuracy of both analytes was calculated and shown in Table-1. Accuracy of chloramphenicol was measured at three levels, 0.128, 3.2, 80 µg/mL and that of prednisolone

Fig. 9. Calibration curve of chloramphenicol

Fig. 10. Calibration curve of prednisolone Acetate

TABLE-1
ACCURACY OF THE PROPOSED LC-DAD METHOD

Drugs	Conc. Spiked (µg/mL)	Conc. detected (µg/mL)	Accuracy (%)	(%RSD)
Chloramphenicol	80	79.86±0.999	99.82	0.12
	3.2	3.199±0.0007	99.97	0.02
	0.128	0.127±0.0007	99.22	0.55
Prednisolone acetate	200	199.5±0.354	99.75	0.18
	8.0	7.98±0.014	99.75	0.17
	0.32	0.319±0.0007	99.69	0.22

acetate was at three different levels, 0.32, 8, 200 µg/mL. Accuracy of the method was found to be well within specified limits. The percent RSD values did not exceed 1 %.

Precision of the method: The intra-day precision was demonstrated in terms of % RSD of three different concentrations by injecting 6 replicate injections of each concentration on same day. The inter-day variability was examined on standard solution up to three concentration levels derived from linearity. % RSD of three concentrations was calculated by injecting 9 replicate injections in 3 days (Table-2).

Robustness studies: Robustness of the method was studied by applying minor variations in the chromatographic conditions like composition of the mobile phase, flow rate, pH of the buffer solution and temperature. Chromatographic parameters such as number of theoretical plates, retention time, tailing factor and impacts on assay were studied¹⁴. Robustness study data of chloramphenicol and prednisolone acetate are presented in Tables 3 and 4, respectively.

TABLE-2
RESULTS OF REPEATABILITY (INTRA-DAY) AND REPRODUCIBILITY (INTER-DAY) STUDIES

Drugs	Conc. spiked (µg/mL)	Intra-day (n = 6)			Inter-day (n = 18)		
		Amount quantitated (µg/mL)	RSD (%)	Accuracy (%)	Amount quantitated (µg/mL)	RSD (%)	Accuracy (%)
Chloramphenicol	0.128	0.126 ± 0.0009	0.714	98.44	0.125 ± 0.001	0.80	97.65
	3.20	3.19 ± 0.004	0.125	99.69	3.19 ± 0.003	0.09	99.69
	80.0	79.04 ± 0.424	0.536	98.81	78.87 ± 0.399	0.506	98.59
Prednisolone Acetate	0.320	0.317 ± 0.001	0.315	99.06	0.316 ± 0.001	0.316	98.75
	8.0	7.95 ± 0.022	0.277	99.37	7.94 ± 0.021	0.264	99.3
	200.0	199.23 ± 0.344	0.173	99.61	198.27 ± 0.612	0.309	99.13

TABLE-5
SPECIFICITY OF THE METHOD

Compounds	Nature of stress	N	% Degradation	% Recovered
Chloramphenicol	HCL (2M) for 20 min	3	2.83	97.17
	NaOH (1.25 M) for 20 min	3	1.17	98.83
	KMNO ₄ (0.006 M) for 30 min	3	0.5	100.7
	Reflux at 120 °C for 2 h	3	1.74	98.26
Prednisolone Acetate	HCL (2M) for 20 min	3	15.57	84.43
	NaOH (1.25 M) for 20 min	3	10.09	89.91
	KMNO ₄ (0.006 M) for 30 min	3	14.74	85.26
	Reflux at 120 °C for 2 h	3	3.34	96.66

TABLE-3
ROBUSTNESS STUDY OF CHLORAMPHENICOL

Chromatographic conditions	Retention time (Rt)	Tailing factor	Theoretical	Assay %
Methanol: buffer (70:30)	2.27	1.342	5220	99.58
Methanol buffer (68:32)	2.348	1.313	4912	100.21
Methanol buffer (72:28)	2.227	1.348	5051	100.57
Flow of rate 1.40 mL min ⁻¹	2.439	1.302	5020	101.05
Flow of rate 1.60 mL min ⁻¹	2.134	1.323	4967	98.93
Buffer pH 3	2.239	1.33	4980	99.25
Buffer pH 3	2.2	1.305	5021	99.69
Column oven 40 °C	2.205	1.335	5475	99.19

TABLE-4
ROBUSTNESS STUDY OF PREDNISOLONE ACETATE

Chromatographic conditions	Retention time (Rt)	Tailing factor	Theoretical	Assay (%)
Methanol: buffer (70:30)	3.659	1.201	6962	99.58
Methanol: buffer (68:32)	4.002	1.164	6644	100.25
Methanol: buffer (72:28)	3.331	1.193	6415	100.42
Flow of rate 1.40 mL min ⁻¹	3.844	1.169	6625	101.1
Flow of rate 1.60 mL min ⁻¹	3.322	1.179	6188	98.9
Buffer pH 3	3.601	1.2	6580	99.93
Buffer pH 3	3.663	1.251	6350	99.1
Column oven 40 °C	3.301	1.19	6891	100.01

Specificity of the method: Specificity of the method was done by performing degradation studies of both the analytes in their mixture form. For this purpose, the analytes were treated with acidic, basic, oxidative and thermal conditions. Chloramphenicol degraded 2.83 % with acidic stress, 1.17 % with basic stress 0.5 % with oxidative stress and 1.74 % with heat stress where as prednisolone acetate degraded 15.57 % with acidic stress, 10.09 % with basic stress, 14.75 % with oxidative stress and 3.34 % with heat stress (Table-5).

System suitability studies:

$$\text{Standard deviation (S)} = \sqrt{\frac{\sum(X_i - \bar{X})^2}{n - 1}}$$

$$= \sqrt{\frac{409029923.200}{4}}$$

$$= 10112.2441$$

$$\text{Relative standard deviation (CV)} = \frac{S \times 100}{\bar{X}}$$

$$(\text{CV}) = \frac{10112.2441 \times 100}{2213024.600}$$

$$(\text{CV}) = 0.46 \%$$

Sr. no.	Xi	(Xi - X)	(Xi - X) ²
1	2199618	-13406.6	179736923.6
2	2214670	1645.4	2707341.16
3	2215800	2775.4	7702845.16
4	2226965	13940.4	194334752.2
5	2208070	-4954.6	24548061.16
X	2213024.6		$\sum(X_i - X)^2 = 409029923$

Conclusion

A simple and reliable method was developed and validated for simultaneous determination of chloramphenicol, prednisolone acetate, excipients and degradation products. Developed method can be used confidently for routine quality control analysis of chloramphenicol and prednisolone acetate as raw active ingredients in eye drops.

ACKNOWLEDGEMENTS

The authors are grateful to The Principal, University College of Pharmacy for providing facilities to complete the required research work. Special thanks are also due to the Principal, Government College University, Lahore for the availability of chemicals.

REFERENCES

1. J.M.L. Gallego and J.P. Arroyo, *J. Pharm. Biomed. Anal.*, **31**, 873 (2003).
2. S.N. Razzaq, I.U. Khan, I. Mariam and S.S. Razzaq, *Chem. Cent. J.*, **6**, 94 (2012).
3. M. Diestelhorst, F. Aspacher, W. Konen, G. Krieglstein and R.D. Hilgers, *Graef. Arch. Clin. Exp.*, **230**, 451 (1992).

4. L. Valvo, A. Paris, A. Savella, B. Gallinella and E.C. Signoretti, *J. Pharm. Biomed. Anal.*, **12**, 805 (1994).
5. S. Ahmed and M. Riaz, *Chromatographia*, **31**, 67 (1991).
6. H. Ashwin, S. Stead, J. Taylor, J. Startin, S. Richmond, V. Homer, T. Bigwood and M. Sharman, *Anal. Chim. Acta*, **529**, 103 (2005).
7. S.G. Musharraf, U. Fatima and R. Sultana, *Chem. Cent. J.*, **6**, 9 (2012).
8. H.T. Rønning, K. Einarsen and T.N. Asp, *J. Chromatogr. A*, **1118**, 226 (2006).
9. M.E. Falagas, A.P. Grammatikos and A. Michalopoulos, *Expert Rev. Anti Infect. Ther.*, **6**, 593 (2008).
10. Y. Hongxin, *Chinese Pharm. Affairs*, **6**, 410 (2007).
11. P. Katakam and K. Sireesha, *Asian J. Pharm. Clin. Res.*, **5**, 182 (2012).
12. D.A. Armbruster, M.D. Tillman and L.M. Hubbs, *Clin. Chem.*, **40**, 1233 (1994).
13. ICH Q2 (R1) Validation of Analytical Procedures: Text and Methodology, http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q2_R1/Step4/Q2_R1__Guideline.pdf (Accessed on 15 March 2014).
14. ICH Harmonised Tripartite Guideline, Validation of Analytical Procedures: Methodology, http://www.hc-sc.gc.ca/dhp-mps/alt_formats/hpfb-dgpsa/pdf/prodpharma/q2b-eng.pdf (Accessed on 02 March 2014).